These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 20981265)
1. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. Ouaïssi M; Giger U; Sielezneff I; Pirrò N; Sastre B; Ouaissi A J Biomed Biotechnol; 2011; 2011():315939. PubMed ID: 20981265 [TBL] [Abstract][Full Text] [Related]
2. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? Koutsounas I; Giaginis C; Theocharis S World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354 [TBL] [Abstract][Full Text] [Related]
5. Current evidence for histone deacetylase inhibitors in pancreatic cancer. Koutsounas I; Giaginis C; Patsouris E; Theocharis S World J Gastroenterol; 2013 Feb; 19(6):813-28. PubMed ID: 23430136 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Feng W; Zhang B; Cai D; Zou X Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202 [TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Xiang XS; Li PC; Wang WQ; Liu L Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188676. PubMed ID: 35016922 [TBL] [Abstract][Full Text] [Related]
8. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455 [TBL] [Abstract][Full Text] [Related]
9. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525 [TBL] [Abstract][Full Text] [Related]
13. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Frew AJ; Johnstone RW; Bolden JE Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapy of cancer with histone deacetylase inhibitors. Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724 [TBL] [Abstract][Full Text] [Related]
15. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090 [TBL] [Abstract][Full Text] [Related]
16. Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer. Ganai SA; Rashid R; Abdullah E; Altaf M Anticancer Agents Med Chem; 2017; 17(3):365-373. PubMed ID: 27281367 [TBL] [Abstract][Full Text] [Related]
17. Effects of novel HDAC inhibitors on urothelial carcinoma cells. Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501 [TBL] [Abstract][Full Text] [Related]
18. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer. Bai Y; Ahmad D; Wang T; Cui G; Li W Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256 [TBL] [Abstract][Full Text] [Related]